The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.

Inclusion Criteria:

• Adult patients aged 18 years or older.
• Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4)
• achieved SVR for HCV after DAAs.

Exclusion Criteria:

• Previous interferon (IFN) treatment.
• Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection.
• Current hepatocellular carcinoma (HCC) or other malignancies.
• Previous history of HCC or HCC intervention.
• Liver cell failure, liver transplantation or renal impairment